Corcept Therapeutics CORT Treasury Stock
Treasury Stock at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:TreasuryStockCommonValue.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's treasury stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's treasury stock?
- Corcept Therapeutics (CORT) reported treasury stock of $976.69M in Q1 2026.
- How has Corcept Therapeutics's treasury stock changed year-over-year?
- Corcept Therapeutics's treasury stock increased by 31.2% year-over-year, from $744.69M to $976.69M.
- What is the long-term trend for Corcept Therapeutics's treasury stock?
- Over 5 years (2020 to 2025), Corcept Therapeutics's treasury stock has grown at a 66.4% compound annual growth rate (CAGR), from $75.8M to $966.59M.
- What does treasury stock mean?
- The cost of shares the company has bought back from the market.
- How do you interpret treasury stock?
- An increase reflects active share buyback programs, often signaling management's confidence in the stock or an effort to return capital to shareholders.
- How does treasury stock compare across companies?
- Common in mature companies; high levels indicate aggressive capital return strategies.